3HAA for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

3HAA for Health & Longevity

Created on 06/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

3HAA is a molecule the body makes when breaking down dietary protein. Raising it made worms and mice live longer and healthier, and it rises in blood after months of exercise. Human evidence is absent, its chemistry can turn harmful around certain metals, and it exists only as a research chemical. (Full Review)

Protocol

Dosing
No validated protocol
No human dosing exists; not an established clinical or supplement intervention.
Route
Endurance exercise
Only approach backed by human data; raised blood 3HAA naturally. Oral supplementation and HAAO inhibition are research routes only.
Half-life
Seconds to minutes
Free 3HAA is cleared by HAAO within seconds to minutes; orally supplied 3HAA is rapidly metabolized.
Time to effect
Lifespan & healthspan
Over the lifespan
Measured over the lifespan in animals; no human time-to-benefit established.
Atherosclerosis
~8 weeks
Atherosclerosis benefits appeared over eight weeks of treatment in mice; unknown in humans.
Exercise-raised 3HAA
~6 months
Six months of endurance exercise raised blood 3HAA by 85–134% in middle-aged adults.

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Children
  • Copper or iron overload disorders
  • Active cancer
  • Significant neurodegenerative or autoimmune disease
    •
Key Interactions
  • IDO/TDO-modulating oncology agents
  • Copper-chelating drugs (penicillamine, trientine)
  • High-dose iron or copper supplements
  • Antioxidant supplements (N-acetylcysteine, vitamin C)
  • Other NRF2-activating compounds (sulforaphane, curcumin)
  • Endurance exercise
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Pro-oxidant toxicity in the presence of metals; conversion toward quinolinic acid
    •
  • Speculative: Unknown effects of chronic human supplementation; disruption of immune balance
    •

Monitoring

Marker Target Why
Ferritin 30–150 ng/mL (women), 50–200 ng/mL (men) Screens for iron overload that amplifies 3HAA pro-oxidant risk
Transferrin saturation 20–40% Detects iron overload (hemochromatosis) before symptoms
Serum copper / ceruloplasmin Copper 70–140 µg/dL Identifies copper excess that catalyzes 3HAA toxicity
hs-CRP <1.0 mg/L Tracks systemic inflammation 3HAA is proposed to lower
ALT/AST <25 U/L Surveillance for unstudied hepatic effects
eGFR >90 mL/min/1.73m² Surveillance for unstudied renal effects

Cadence: Baseline, at roughly 4–8 weeks, then every 3–6 months, with prompt re-checking if any new symptom arises

Qualitative Assessment

  • Energy and vitality through the day
  • Cognitive clarity and absence of new neurological symptoms
  • Sleep quality
  • Exercise recovery and tolerance
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.